Sanofi–GSK COVID-19 vaccine (redirect from Vidprevtyn Beta)
The Sanofi–GSK COVID-19 vaccine sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK. The Sanofi–GSK COVID‑19...
19 KB (1,426 words) - 20:52, 3 September 2024
Archived from the original on 30 December 2021. Retrieved 19 January 2022. "VidPrevtyn Beta". European Medicines Agency (EMA). 4 November 2022. Archived from...
200 KB (22,796 words) - 05:34, 12 September 2024
Zealand Turkey The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a subunit vaccine developed by Sanofi Pasteur and GSK plc. It...
322 KB (19,558 words) - 03:33, 16 September 2024
20 December 2021 21 March 2022 VLA2001 24 June 2022 9 September 2022 VidPrevtyn Beta 10 November 2022 12 December 2022 Bimervax (COVID-19 Vaccine HIPRA)...
60 KB (2,698 words) - 12:24, 27 July 2024
old, arriving in Bulgaria in late October 2022. On 10 November 2022, VidPrevtyn Beta received EMA's and the European Commission's authorization, with...
453 KB (34,260 words) - 11:32, 13 September 2024
response Pending authorization Sanofi–GSK COVID-19 vaccine (VAT00008, Vidprevtyn) Sanofi Pasteur, GSK France, United Kingdom Subunit (SARS-CoV-2 S adjuvanted...
95 KB (18,965 words) - 23:35, 15 September 2024
vicriviroc (USAN) Victoza vidarabine (INN) Vidaza Videx vidofludimus (INN) Vidprevtyn Beta vidupiprant (INN) Viekirax Vienva vigabatrin (INN) Vigadrone Vigafyde...
8 KB (433 words) - 23:34, 13 September 2024